Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
73
datasets available to search
ShareScore release 0.9.0
Dataset results
73 results for “Parkinson's disease','biomarkers”
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
<p>Annotated WES VCF file and phenotype file used in Gene burden analysis of Naaldijk et al., "A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells", 2023. </p><p> </p>
Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease
<p><strong>Abstract: </strong>We address an unmet challenge in Parkinson’s disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. The gut microbiome is a new target for treatment of neurodegenerative diseases. Our aim was to develop microbiome-based biomarkers to guide patient selection for microbiome-based clinical trials. We used microbial taxa that are robustly associated with PD across studies and at high significance as dysbiotic features of PD. Using individual-level taxonomic relative abundance data, we classified patients according to their dysbiotic features, effectively defining microbiome-based subtypes of PD. We show that not all persons with PD have a dysbiotic microbiome, and not all dysbiotic PD microbiomes have the same features. Grounded in robust and reproducible data from differential abundance studies, we propose an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual’s dysbiotic features. We demonstrate the method for PD. The concept, and the method, is generalizable for any disease with a microbiome component.</p> <p><strong>Zenodo</strong> <strong>content: </strong>In this Zenodo archive we provide (a) the method described step by step, which can be implemented in Microsoft Excel (we used v.16.84 (RRID:SCR_016137) <a href="https://www.microsoft.com/en-gb/">https://www.microsoft.com/en-gb/</a>) or in R (we used v4.3.3 (RRID:SCR_001905) <a title="https://www.r-project.org/ Cmd+Click or tap to follow the link" href="https://www.r-project.org/">https://www.r-project.org/</a>); and (b) data used to generate the results, tables and figures (except figure 2). Data for creating figure 2 can be found in source data (doi: 10.5281/zenodo.7246185) and the method is described by Wallen et al 2022 (DOI: <u><a href="https://doi.org/10.1038/s41467-022-34667-x" target="_blank" rel="noopener">10.1038/s41467-022-34667-x</a></u>). All data used here were extracted from the original source data reported by<strong> </strong>Wallen et. al. 2022 (DOI: <u><a href="https://doi.org/10.1038/s41467-022-34667-x" target="_blank" rel="noopener">10.1038/s41467-022-34667-x</a></u>) which can be found on Zenodo (DOI: 10.5281/zenodo.7246185).</p>
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
ClinicalTrials.gov study NCT01106976. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Imaging Biomarkers in Parkinson s Disease
ClinicalTrials.gov study NCT01496599. IPD Sharing: YES. Countries: 1. Publications: 3.
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
ClinicalTrials.gov study NCT02954978. IPD Sharing: NO. Countries: 1. Publications: 4.
Biomarkers to Guide Directional DBS for Parkinson's Disease
ClinicalTrials.gov study NCT03353688. IPD Sharing: YES. Countries: 1. Publications: 1.
Acute Effects of Medium Chain Triglyceride (MCT) Nutritional Ketosis on Parkinson's Disease (PD) Symptoms and Biomarkers (MCT-PD)
ClinicalTrials.gov study NCT04584346. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Data from: Blood NfL: a biomarker for disease severity and progression in Parkinson's disease
Objective: To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson's disease (PD). Methods: This prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition, at baseline and at a mean follow-up interval of 3 years. Changes in the unified Parkinson's disease rating scale (UPDRS) part III motor score and Mini-Mental State Examination (MMSE) score were used to assess motor and cognition progression. Results: Plasma fL levels were significantly higher in MSA than in PD and healthy groups (35.8±6.2 pg/ml, 17.6±2.8 pg/ml, and 10.6±2.3 pg/ml, respectively; P<0.001). In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr (H-Y) stage and patients with dementia (PDD) (P<0.001). NfL levels were modestly correlated with UPDRS part III scores (r=0.42, 95% CI: 0.46-0.56, P<0.001). After a mean follow-up of 3.4±1.2 years, a Cox regression analysis adjusted for age, sex, disease duration and baseline motor or cognitive status showed that higher baseline NfL levels were associated with higher risks for either motor or cognition progression (P=0.029 and P=0.015, respectively). Conclusions: Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. Classification of evidence: This study provides Class III evidence that plasma NfL levels distinguish PD and MSA, and is a surrogate biomarker for PD progression.
Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
ClinicalTrials.gov study NCT03790670. IPD Sharing: NO. Countries: 1. Publications: 5.
Digital BIOmarkers for the Assessment of Motor Status in Parkinson's Disease Patients with CLInical and ThErapeutic Application
ClinicalTrials.gov study NCT06817772. IPD Sharing: NO. Countries: 1. Publications: 2.
Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease
ClinicalTrials.gov study NCT05385315. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Biomarkers of Neurodegeneration and Neuroplasticity in Parkinson's Disease Patients Treated by Bilateral M1-iTBS
ClinicalTrials.gov study NCT06840145. IPD Sharing: YES. Countries: 1. Publications: 1.
Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
ClinicalTrials.gov study NCT03716258. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson's Disease
ClinicalTrials.gov study NCT05452655. IPD Sharing: NO. Countries: 1. Publications: 1.
New Biomarkers in Parkinson's Disease
ClinicalTrials.gov study NCT05150158. IPD Sharing: UNDECIDED. Countries: 1. Publications: 12.
Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
ClinicalTrials.gov study NCT05677633. IPD Sharing: NO. Countries: 1. Publications: 3.
Parkinson's Disease Biomarker Program
ClinicalTrials.gov study NCT01767818. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
ClinicalTrials.gov study NCT06621602. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
ClinicalTrials.gov study NCT00273351. IPD Sharing: Not stated. Countries: 1. Publications: 12.
Effects of Nordic Walking Exercise on Gait, Motor/Non-motor Symptoms, and Exercise Biomarkers in Parkinson's Disease
ClinicalTrials.gov study NCT04237025. IPD Sharing: NO. Countries: 1. Publications: 13.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.